| Validity of ADHD Subtypes Using Neuropsychological Measure (NCT00494819) | National Taiwan University Hospital | 2005-09-01 |
| Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (NCT00399763) | Denver Health and Hospital Authority | 2005-09-01 |
| Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD (NCT00305370) | Federal University of Rio Grande do Sul | 2005-08-01 |
| Magnetic Resonance Imaging of Brain Development in Attention Deficit Hyperactivity Disorder (NCT00143767) | UMC Utrecht | 2005-08-01 |
| Sleep and Nocturnal Melatonin in Adults With Attention Deficit Hyperactivity Disorder (ADHD) (NCT01329510) | Assaf-Harofeh Medical Center | 2005-08-01 |
| CX717 in the Treatment of Adult ADHD (NCT03375021) | RespireRx | 2005-07-19 |
| Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility (NCT00953862) | NYU Langone Health | 2005-07-01 |
| The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents (NCT00566371) | Rhode Island Hospital | 2005-06-01 |
| Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder (NCT00190879) | Eli Lilly and Company | 2005-06-01 |
| Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) (NCT00191945) | Eli Lilly and Company | 2005-05-01 |
| Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder) (NCT00221962) | University Hospitals Cleveland Medical Center | 2005-04-01 |
| Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes (NCT00191633) | Eli Lilly and Company | 2005-04-01 |
| Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) (NCT00191906) | Eli Lilly and Company | 2005-04-01 |
| Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents (NCT00191542) | Eli Lilly and Company | 2005-03-01 |
| Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD) (NCT00116259) | Federal University of Rio Grande do Sul | 2005-03-01 |
| Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD) (NCT00100295) | National Center for Complementary and Integrative Health (NCCIH) | 2005-02-01 |
| Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD) (NCT00191295) | Eli Lilly and Company | 2005-02-01 |
| A Follow-up, Family Study on Attention-deficit Hyperactivity Disorder (NCT00417781) | National Taiwan University Hospital | 2005-01-01 |
| Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD (NCT00619840) | Medice Arzneimittel Pütter GmbH & Co KG | 2004-11-01 |
| OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD (NCT02215538) | University of Utah | 2004-11-01 |
| An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). (NCT00192023) | Eli Lilly and Company | 2004-10-01 |
| An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (NCT00191516) | Eli Lilly and Company | 2004-10-01 |
| An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder (NCT00191737) | Eli Lilly and Company | 2004-10-01 |
| Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD (NCT00556296) | New River Pharmaceuticals | 2004-10-01 |
| A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) (NCT00190775) | Eli Lilly and Company | 2004-09-01 |
| Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning (NCT00143832) | UMC Utrecht | 2004-09-01 |
| Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD (NCT00382616) | Tel-Aviv Sourasky Medical Center | 2004-07-01 |
| The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) (NCT00928148) | Shire | 2004-06-14 |
| Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory (NCT00530257) | Children's Hospital of Philadelphia | 2004-06-01 |
| Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents (NCT00191659) | Eli Lilly and Company | 2004-06-01 |
| Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD (NCT00485875) | Eli Lilly and Company | 2004-06-01 |
| Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder (NCT00191880) | Eli Lilly and Company | 2004-05-01 |
| Atomoxetine Pilot Study in Preschool Children With ADHD (NCT00517647) | University of Arizona | 2004-04-01 |
| Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD (NCT00191035) | Eli Lilly and Company | 2004-03-01 |
| A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD (NCT00485849) | Eli Lilly and Company | 2004-02-01 |
| Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD (NCT00585910) | Massachusetts General Hospital | 2004-01-01 |
| Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy (NCT00485550) | Eli Lilly and Company | 2004-01-01 |
| Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD (NCT00486083) | Eli Lilly and Company | 2003-12-01 |
| Resources to Enhance the Adjustment of Children (REACH) (NCT00820001) | University of Pittsburgh | 2003-12-01 |
| Fatty Acids and Attention Deficit and Hyperactivity Disorder Symptoms (NCT03283579) | Barcelona Institute for Global Health | 2003-11-01 |
| Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD (NCT00191048) | Eli Lilly and Company | 2003-10-01 |
| Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD (NCT00214981) | Cephalon | 2003-09-01 |
| Preschool Supplement to Clonidine in ADHD (Kiddie-CAT) (NCT00414921) | University of Cincinnati | 2003-09-01 |
| Evaluation of Continuous Symptom Treatment of ADHD (NCT00486122) | Eli Lilly and Company | 2003-09-01 |
| Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder (NCT00467428) | NeuroSearch A/S | 2003-08-01 |
| Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine (NCT00485407) | Eli Lilly and Company | 2003-07-01 |
| Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate (NCT00302406) | Massachusetts General Hospital | 2003-07-01 |
| Safety Study in Outpatient Japanese Children With ADHD (NCT00485628) | Eli Lilly and Company | 2003-04-01 |
| Mental Health Services for Foster and Adopted Children (NCT00056303) | University of Delaware | 2002-12-01 |
| The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting (NCT00381758) | UCB Pharma | 2002-05-01 |
| Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers (NCT00026546) | National Institute of Mental Health (NIMH) | 2001-11-07 |
| Methylphenidate Study in Young Children With Developmental Disorders (NCT00517504) | University of Arizona | 2001-05-01 |
| Treatment of Youth With ADHD and Anxiety (NCT00012584) | National Institute of Mental Health (NIMH) | 2000-11-01 |
| An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD (NCT00302380) | Massachusetts General Hospital | 2000-10-01 |
| Long-Term, Open Label Atomoxetine Study (NCT00190684) | Eli Lilly and Company | 2000-08-01 |
| Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD) (NCT00483106) | McGill University | 1999-11-01 |
| Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder (NCT00161161) | UMC Utrecht | 1999-10-01 |
| An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder (NCT00269776) | Alza Corporation, DE, USA | 1998-11-01 |
| A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children (NCT00269789) | Alza Corporation, DE, USA | 1998-03-01 |
| Johnston County ADHD Study: Environmental, Reporductive, and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD) (NCT00339729) | National Institute of Environmental Health Sciences (NIEHS) | 1997-05-07 |
| Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers (NCT00001246) | National Institute of Mental Health (NIMH) | 1990-06-19 |
| Further Studies of Attention Deficit Disorder - Residual Type (RT) (NCT00693212) | University of Utah | 1986-02-01 |
| Dextromethorphan Added on for the Patients With ADHD (NCT01787136) | Tri-Service General Hospital (TSGH) | |
| An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children (NCT00304681) | Janssen-Ortho Inc., Canada | |
| Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder (NCT00269815) | Alza Corporation, DE, USA | |
| Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD (NCT01207622) | Massachusetts General Hospital | |
| Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder (NCT00866996) | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | |
| Procedural Learning in Participants With ADHD (NCT00446537) | Shaare Zedek Medical Center | |
| A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder (NCT00269802) | Alza Corporation, DE, USA | |